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Summary 
Three galenic formulations of Cefixime (tablet, syrup and 
dry suspension) containing 200 mg each were compared 
with respect to their relative bioavailability in twelve 
healthy volunteers. All three formulations showed reliable 
absorption. Mean peak plasma concentrations were 
reached after 3.3—3.5 h, mean terminal half lives were 
2.9—3.1 h. 18—24 % of the dose administered were re-
covered unchanged in the urine. Best bioavailability was 
obtained with the dry suspension (AUC0.M =25.8 ± 7.0 
ug/ml h; Cmax = 3.4 ± 0.9 pg/ml), followed by the tablet 
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(AUC0_„ = 20.9 ± 8.1 pg/ml h; Cmax = 3.0 ± 1.0 jug/ml) 
and the syrup which is based on triglycerides (AUC(hoo = 
17.8 ± 5.9 pg/ml h; Cmax = 2.4 ± 0.7 pg/ml). The statis-
tical analysis resulted in bioinequivalence between dry sus-
pension and syrup. It is concluded that best bioavailability 
of Cefixime after oral administration is guaranteed when 
taken in an "aqueous medium " either as dry suspension 
or as tablet with "plenty of liquid". 
Zusammenfassung 
Relative Bioverfügbarkeit von drei galenischen Cefixim-
Formulierungen 
Die relative Bioverfügbarkeit dreier galenischer Formulie-
rungen von Cefixim (Tablette, Fertigsaft und Trockensu-
spension) mit je 200 mg Wirkstoff wurde bei zwölf frei-
willigen Probanden verglichen. Alle Formulierungen zeig-
ten eine zuverlässige Absorption von Cefixim, die mitt-
leren Maximalkonzentrationen wurden im Plasma nach 
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3.3—3.5 h erreicht. Die mittleren Plasmahalbwertszeiten 
betrugen 2.9—3.1 h. 18—24 % der Dosis wurden im Urin 
unverändert wiedergefunden. Die beste Bioverfügbarkeit 
gewährleistet die Trockensuspension (AUC0^ =25,8 ± 
7,0 pg/ml h; Cmax = 3,4 + 0,9 jig/ml), gefolgt von der Ta-
blette (AUCooo =20,9 ± 8,1 ixg/ml h; Cmax 3,0 ± 1,0 ßg/ 
ml) und dem Fertigsaft, der auf Triglyceriden basiert 
(AUC0.„ - 17,8 ± 5,9ßg/ml h; C„mx = 2,4 ± 0,7 jug/ml). 
Die statistische Analyse ergab Bioinäquivalenz zwischen 
Trockensuspension und Fertigsaft. Es wird geschlossen, 
daß die bestmögliche Bioverfügbarkeit von Cefixim nach 
oraler Applikation resultiert, wenn der Wirkstoff in einem 
„wäßrigen Medium" eingenommen wird, entweder als 
Trockensuspension oder Tablette mit „reichlich Flüssig-
keit". 
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1. Introduction 
Cefixime (see structural formula) is an orally absorbed 
cephalosporin with pharmacodynamic characteristics of 
the third generation cephalosporins for parenteral use 
(Bauernfeind 1985). As with other new oral cephalospo-
rins (carboxymethyl and pro-drug cephalosporins, 
Dürckheimer et al. 1987) the pharmacokinetic behaviour 
of Cefixime is characterized by incomplete bioavailability 
after oral administration (Faulkner et al. 1987). The aim 
of the present study was to investigate the influence of 
three different galenic formulations (tablet, syrup and dry 
suspension) on the bioavailability of Cefixime. 
Table 1: Demographic data of volunteers and sequence of drug administra-
tion (A, tablet; B, syrup; C, dry suspension). 
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Chemical structure of Cefixime 
2. Materials and methods 
2.1. Drug formulations, reagents and chemicals 
Cefixime as tablet (containing 200 mg; batch No . Z 050 0348), 
syrup and dry suspension (containing 200 mg p e r 10 m l ; batch 
No . Z 050 0122 and N o . Z 050 0362) as well as C e f i x i m e stan-
dard substance were obtained from E. Merck , Darmstadt ( F R G ) . 
te trabutylammonium hydrogensulfate (puriss.) from Fluka , 
N e u - U l m ( F R G ) , all other chemicals (analytical or H P L C grade) 
from E . Merck . Water was purified by a M i l l i - Q water purifica-
tion system. Mi l l i po re , Eschborn ( F R G ) . 
2.2. Clinical part 
Twelve volunteers (6 male, 6 female, Table 1) aged 21 to 43 (me-
dian 28) years, a body weight of 56 to 89 (median 75) kg, and a 
height o f 159 to 190 (median 174) cm were entered into the 
study. The study was performed according to the legal aspects o f 
the F R Germany and the revised Declarat ion of Hels ink i . Wr i t -
ten informed consent was obtained from each volunteer. The 
health status of each subject was assessed by routine physical 
examination and laboratory analysis. Each subject was randomly 
assigned in a three-way crossover design to receive 200 mg Ce-
fixime orally as a tablet, syrup and dry suspension. Dosing per -
iods were separated by one week. The doses were administered 
with 100 ml o f water after an overnight fast and each subject 
fasted for further 4 h. Thereafter a standard meal was given. 
Venous blood samples (by A m m o n i u m Heparin Monovet te®, 
Sarstedt. N ü m b r e c h t . F R G ) were taken from an arm vein prior 
to dosing and at 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4. 5, 6. 8, 10. 12 and 
24 h after dosing. Ur ine was collected prior to, and at 0—2. 2— 
4, 4—8, 8—12 and 12—24 h intervals after dosing. Al iquots o f 
plasma and urine were stored at —70 °C until assayed. 





1 H.S. m 33 73 183 C-A-B 
2 C.N. m 21 89 190 A-B-C 
3 K . H . m 24 80 188 B-C-A 
4 F L . m 28 88 188 B-C-A 
5 H.A. m 28 85 180 A-B-C 
6 W.D. m 37 81 174 C-A-B 
7 G.S. f 33 62 166 C-A-B 
8 A.S. f 24 57 162 A-B-C 
9 G.P. f 37 64 159 B-C-A 
10 K . E . f 21 68 165 A-B-C 
11 P.S. f 25 56 164 C-A-B 













2.3. Drug assay 
Concentrations of C e f i x i m e were determined by a high-perform-
ance l iqu id chromatographic ( H P L C ) assay (Kees e l al. 1984. 
1987). In brief, 200 u l plasma were buffered with 200 u l 50 
mmol/1 sodium dihydrogen phosphate and deproteinized with 
400 ul acetonitrile. The protein was separated by centrifugation 
and the acetonitrile removed by extraction with dichloro meth-
ane. Ur ine was centrifuged and diluted 1 :10 with 20 mmol/1 
sodium phosphate, p H 6.5. 50 ul (urine: 5 ul) o f the aqueous 
layer were injected onto the H P L C column. 
The chromatographic svstem consisted o f a pump M 6 0 0 0 A . a n 
autosampler W I S P 71ÖB. a N o v a p a k - C184 u rn 100 x 5 m m 
polyethylene cartridge housed i n a compression module R C M 
100, a fixed-wavelenght U V detector M 4 4 0 (280 nm). a data 
module M 7 3 0 , and a system controller M 7 2 0 (all from M i l l i p o r e 
Waters-Chromatography. Eschborn. F R G ) . The eluent was a 
mixture of 800 m l water, 1.38 g sodium dihydrogen phosphate 
monohydrate, 1.00 g tetrabutylammonium hydrogensulfate. and 
220—250 ml acetonitrile (pH 6.6 with 10 N sodium hydroxide). 
A t a flow rate of 1.0 m l / m i n (back pressure 60 bar) the retention 
time of C e f i x i m e was 4.0—4.8 min (Fig. 1). 
The recovery of C e f i x i m e from plasma was quantitative 
(101 ± 2 % , n = 12, concentration 5 u g / m l ) . standard curves 
from 0.1 to 5 ug/ml were found to be linear (r > 0.99990). the 
lower l imi t of quantification i n plasma was 0.1 u g / m l , the coef-
ficient of variation for control samples 2.3 and 7.6 % (cone. 2.7 
and 0.27 jag/ml). In urine the l imi t o f quantification was 1—2 ug/ 
m l because of higher chromatographic background, especially in 
morning urine (compare Fig . 1). 
2.4. Data analysis 
Pharmacokinetic parameters for C e f i x i m e were estimated using 
model-independent methods. The peak plasma concentration 
( C m a x ) and the time to reach C m a N ( T m a x ) were determined by 
visual inspection of the plasma concentration versus time data. 
Values for the el imination rate constant ( k d ) and terminal half-
life ( T i / : ) were estimated by linear regression o f the semi-loga-
r i thmic plot of the last 4 or 5 plasma concentrations versus time. 
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Fig. 1: Chromatograms o f plasma and urine of a subject (no. 8) pr ior to 
and after oral adminis t rat ion o f 200 mg Cefixime. The asterisk (*) marks 
the posit ion o f the Cefixime peak. 
The area under the plasma concentration-time curve (AUCo-«,) 
was estimated by the trapezoidal rule and extrapolated to infin-
ity. The extrapolation was performed by d iv id ing the last meas-
urable concentration by the e l iminat ion rate constant ( k d ) . Re-
covery o f unchanged Cefixime in urine was calculated as per-
centage o f the administered dose. 
For statistical analysis o f bioavai labi l i ty of the three oral Cefix-
ime formulations a computer program was used (BIO Q , Stein-
ijans and Di le t t i 1983a, b). 
3. Results 
The plasma concentrations of Cefixime after administra-
tion of the three different formulations are compiled in 
Table 2 (p. 296), the mean values are shown in Fig. 2, the 
estimated pharmacokinetic parameters in Table 3 (p. 
296). Very similar mean values were found for terminal 
half-life, 2.9 to 3.1 h, and time of peak plasma concen-
trations, 3.3 to 3.5 h, whereas greater differences were 
seen in peak plasma concentrations: 2.95 ± 0.99 ug/ml 
(tablet), 2.43 ± 0.68 ug/ml (syrup) and 3.41 ± 0.92 ug/ 
ml (dry suspension), and AUCs: 20.9 ± 8.1 ug/ml h (tab-
let), 17.8 ± 5.9 ug/ml h (syrup) and 25.8 ± 7.0 ug/ml h 
(dry suspension). Mean urinary recovery of unchanged 
Cefixime accounted for 18—24 % (Table 3). 
From inspection of mean values the following order of 
bioavailability of Cefixime can be deduced: dry suspen-
sion > tablet > syrup. The statistical analysis (paired t-
test) revealed significant differences between dry suspen-
sion and syrup with respect to A U C (p < 0.001) and uri-
nary recovery (p < 0.05), and between dry suspension 
and tablet with respect to A U C (p < 0.001). Bioequival-
ence could not be proved between dry suspension and 
tablet, whereas bioinequivalence was found between dry 
suspension and syrup (Table 4) by comparison of the in-
dividual ratios of A U C and C m a x . 
Tables 2 and 3 see p. 296. 
4. Discussion 
A major disadvantage of the newer oral cephalosporins 
of the carboxymethyl and pro-drug type compared with 
classical oral cephalosporins of the cephalexin type is in-
complete absorption from gastrointestinal tract (Diirck-
heimer et al. 1987). The absolute bioavailabilities of the 
active drugs don't exceed 50 %. This was shown for Ce-
fixime (Faulkner et al. 1987), cefuroxime axetil (Williams 
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Fig. 2: Mean plasma concentrations (ug/ml) of Cefixime in twelve healthy 
volunteers after oral administration of 200 mg as tablet, syrup and dry 
suspension; • = tablet. + = syrup, O = dry suspension. 
Table 4: Test for bioequivalence between three formulations of Cefixime 
(lest/reference; Pitman's permutation tst; abbr.: A. tablet: B ? syrup; C, dry-
suspension. 
A U C 0 _ . cm a x 
Test/ref. point 95 %- point 
95 %-
confidence confidence 
estimate interval estimate interval 
B/A 0.88 0.72-1.08 0.84 0.73-0.98 
C/A 1.28 1.12-1.47 1.19 1.04-1.33 
C/B 1.46 1.20-1.77 1.40 1.19-1.64 
and Harding 1984), cefotiam hexetil (SCE-2174, Couet 
et al. 1987) and Cefetamet pivoxil (Koup et al. 1988). In 
this study a syrup formulation of Cefixime which is based 
on triglycerides (MCTs) like a commercially available ce-
faclor syrup was compared with a tablet and dry suspen-
sion formulation. It resulted that the syrup showed the 
lowest bioavailability of Cefixime although medium 
chain glycerides and fatty acids may promote intestinal 
absorption of ß-lactam antibiotics, e.g. cefoxitin (Van 
Hoogdalem et al. 1989 and references cited). The highest 
bioavailability showed the dry suspension in which (after 
combination with water prior to administration) Cefix-
ime is partially dissolved. This is in agreement with pre-
vious results of Faulkner et al. 1987, who found slightly 
higher areas under the plasma concentration-time curve 
after administration of 200 mg Cefixime as an aqueous 
solution with respect to a capsule formulation (average 
26 versus 23 mg/1 h) which resembles the tablet. 
The plasma concentration-time curve could not be fitted 
by a computer program assuming first-order absorption 
and elimination processes. Presumably, a better fit would 
result assuming a zero-order absorption process (c.f. 
Hespe et al. 1987) because of presumably transmembrane 
rate-limited absorption of Cefixime and other oral ß-lac-
tam antibiotics (c.f. Nakashima et al. 1984, Okano et al. 
1986, Tsuji et al. 1987). The delayed peak plasma con-
centrations (3 h) despite fasting administration of the 
drug and the non-proportionality of bioavailability with 
increasing doses (Faulkner et al. 1987) would agree with 
this model. Nevertheless, the percentage of Cefixime ab-
sorbed was reliable in all three formulations as can be 
seen from the moderate coefficients of variance of aver-
age AUCs (27—39 %) and peak plasma concentrations 
(27-34 %). 
Tablet 
Subject 1 2 3 4 5 6 7 8 9 10 1 1 12 Mean SD 
Time (h) 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 
0.33 0.52 0.00 0.39 0.13 0.13 0.30 0.07 0.09 0.37 1.22 0.25 0.35 0.319 0.324 
0.67 1.00 0.00 0.91 0.31 0.34 0.66 0.30 0.28 1.16 1.98 0.58 0.84 0.696 0.533 
1.00 1.31 0.00 1.26 0.55 0.67 1.07 0.81 0.49 1.79 2.60 1.07 1.22 1.070 0.670 
1.50 1.68 0.00 1.75 1.14 1.06 1.88 2.00 1.06 2.73 3.27 1.77 1.68 1.668 0.834 
2.00 1.93 0.21 1.94 2.05 1.35 2.14 2.97 1.89 3.33 3.45 2.67 1.92 2.155 0.888 
2.50 2.11 0.48 2.14 2.66 1.50 2.29 3.48 2.69 3.55 3.76 2.96 2.33 2.498 0.922 
3.00 2.03 0.87 2.21 3.23 1.71 2.59 3.88 3.19 3.66 3.81 3.29 2.30 2.731 0.933 
4.00 1.54 1.42 2.09 3.54 1.54 2.44 4.51 3.98 3.64 3.14 3.36 2.46 2.805 1.035 
5.00 1.21 1.35 1.57 3.24 1.35 1.86 3.89 3.77 3.28 2.41 2.96 1.94 2.403 0.986 
6.00 0.86 1.10 1.31 2.60 1.10 1.71 3.32 3.39 2.64 1.94 2.53 1.68 2.017 0.870 
8.00 0.54 0.66 0.80 1.87 0.63 1.09 2.19 2.26 1.66 1.07 1.54 1.03 1.278 0.609 
10.00 0.28 0.46 0.46 1.13 0.42 0.67 1.41 1.37 0.91 0.64 0.99 0.63 0.783 0.376 
12.00 0.14 0.23 0.26 0.78 0.27 0.44 0.91 0.83 0.53 0.33 0.61 0.29 0.469 0.261 
24.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.00 0.00 0.00 0.00 
Synip 
Subject 1 2 3 4 5 6 7 8 9 10 1 1 12 Mean SD 
Time (h) 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.33 0.20 0.09 0.47 0.47 0.22 0.23 0.62 0.54 0.32 0.42 0.14 0.14 0.323 1.176 
0.67 0.33 0.35 0.80 1.05 0.56 0.62 0.91 0.95 0.62 0.71 0.30 0.33 0.628 0.264 
1.00 0.54 0.60 0.91 1.49 0.77 0.77 1.12 1.25 0.86 1.06 0.72 0.56 0.888 0.294 
1.50 1.03 0.83 1.45 2.29 1.06 1.49 1.34 1.63 1.20 1.42 1.27 0.95 1.332 0.386 
2.00 1.65 1.34 1.44 3.09 1.35 1.71 1.77 2.17 1.75 1.98 1.67 1.50 1.784 0.479 
2.50 1.92 1.51 1.57 3.06 1.44 1.86 2.19 2.64 2.13 2.25 1.91 2.07 2.046 0.468 
3.00 2.01 1.75 1.49 3.37 1.57 1.75 2.58 2.93 2.34 2.54 2.27 2.49 2.258 0.572 
4.00 1.87 1.70 1.39 3.49 1.50 1.80 3.01 3.33 2.39 2.38 2.58 3.07 2.376 0.731 
5.00 1.47 1.28 1.07 2.84 1.38 1.40 2.66 3.22 2.10 1.80 2.00 3.03 2.021 0.748 
6.00 1.12 1.20 0.80 2.33 1.23 1.08 2.22 2.92 1.78 1.45 1.76 2.59 1.705 0.677 
8.00 0.60 0.82 0.46 1.45 0.91 0.66 1.29 2.11 1.25 0.75 0.97 1.54 1.067 0.477 
10.00 0.37 0.52 0.26 0.90 0.66 0.39 0.76 1.29 0.76 0.43 0.54 1.00 0.657 0.301 
12.00 0.22 0.28 0.19 0.53 0.56 0.31 0.45 0.80 0.51 0.25 0.34 0.70 0.429 0.196 
24.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00 0.00 
Dry sjispension 
Subject 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Time (h) 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.33 0.26 0.52 0.87 0.85 0.43 0.42 0.62 0.07 0.16 0.70 0.14 0.12 0.431 0.286 
0.67 0.70 0.99 1.36 1.49 0.70 0.97 1.36 0.43 0.53 1.71 0.37 0.45 0.923 0.463 
1.00 0.97 1.27 1.82 1.93 1.17 1.45 1.97 0.70 0.74 2.48 0.75 0.74 1.334 0.597 
1.50 1.67 1.79 2.58 2.72 1.44 2.14 2.74 1.34 1.96 3.80 1.61 1.53 2.1 1 1 0.725 
2.00 2.14 2.16 2.87 3.20 1.62 2.86 3.24 2.38 3.17 4.48 2.72 1.96 2.733 0.762 
2.50 2.72 2.27 2.86 3.57 1.55 2.94 3.47 2.99 3.89 4.70 3.21 2.57 3.061 0.807 
3.00 3.20 2.25 2.81 3.87 1.55 3.14 3.62 3.51 4.33 4.78 3.58 2.67 3.275 0.886 
4.00 3.28 2.04 2.66 3.97 1.49 3.06 3.67 3.85 4.52 4.48 4.07 2.91 3.333 0.944 
5.00 2.85 1.93 2.09 3.54 1.24 2.61 3.19 3.48 3.84 3.68 3.66 2.68 2.899 0.821 
6.00 2.24 1.56 1.55 2.92 1.05 2.01 2.96 3.44 3.61 2.83 3.08 2.29 2.460 0.807 
8.00 1.39 0.99 1.01 2.07 0.66 1.43 1.69 2.31 2.50 1.56 2.08 1.68 1.614 0.561 
10.00 0.80 0.57 0.56 1.25 0.39 0.85 1.20 1.38 1.49 0.81 1.36 1.16 0.986 0.366 
12.00 0.42 0.28 0.32 0.77 0.32 0.59 0.76 0.88 0.85 0.45 0.85 0.73 0.602 0.233 
24.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00 
Table 3: Pharmacokinetic parameters (mean, SD, range) of Cefixime in twelve healthy volunteers after oral administration of 200 mg Cefixime as tablet, 
syrup and dry suspension. Abbr.: C m a x , maximum plasma concentration; T n , ; i x , time of peak plasma concentration; T i / 2 . terminal plasma half-life; AUC, , 
„, area under the plasma concentration-time curve from time zero to infinity; U 0 _ > 4 h - recovery of unchanged Cefixime in urine up to 24 h after dosage. 
Parameter 
Tablet Syrup Drv suspension 
Dimension 
mean SD range mean SD range mean SD range 
c m a x (am/ml 2.95 0.99 1.42- 4.51 2.43 0.68 1.57- 3.49 3.41 0.92 1.62- 4.78 
T|i ia\ h 3.46 0.58 2.50- 4.00 3.42 0.63 2.50- 4.00 3.33 0.89 2.00- 4.00 
h 2.91 0.43 2.36- 3.97 3.13 0.61 2.44- 4.63 3.01 0.43 2.35- 3.80 
A U C 0 _ , jig/ml h 20.89 8.08 8.96-33.44 17.83 5.89 10.15-29.28 25.84 6.99 12.50-34.42 
U<>-2,h % of dose 22.09 9.82 4.29_40.48 18.38 6.03 6.16-28.51 24.13 8.14 10.48-38.85 
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